Figure S3.
Inhibition of SPT disrupts nuclear morphology in human cells. (a) Western blot of SPT subunits in RPE-1 upon their knockdown for 48 h. (b) Cell proliferation of RPE-1 upon knockdown of SPTLC1 or SPTLC2. Error bars represent standard deviations (n = 3). *P < 1e-4, one-way ANOVA. (c) FACS profiles of cells stained with BrdU upon knockdown of SPTLC1 or SPTLC2. (d) Schematic of target enzymes by the different drugs used in our experiments. (e) Representative images of RPE-1 cells in media containing 10% FBS in the presence of 250 nM Torin, 10 µM TOFA, 10 µM cerulenin, 40 µM C75, or 1 µM lovastatin. Blue, Hoechst 33342 (DNA); green, anti-lamin B1 (NE). Scale bar, 5 µm. (f) Circularity of 200 nuclei for each condition in Fig. S3 e. (g) FACS profiles of cells in each condition in Fig. S3 e. Source data are available for this figure: SourceData FS3.

Inhibition of SPT disrupts nuclear morphology in human cells. (a) Western blot of SPT subunits in RPE-1 upon their knockdown for 48 h. (b) Cell proliferation of RPE-1 upon knockdown of SPTLC1 or SPTLC2. Error bars represent standard deviations (n = 3). *P < 1e-4, one-way ANOVA. (c) FACS profiles of cells stained with BrdU upon knockdown of SPTLC1 or SPTLC2. (d) Schematic of target enzymes by the different drugs used in our experiments. (e) Representative images of RPE-1 cells in media containing 10% FBS in the presence of 250 nM Torin, 10 µM TOFA, 10 µM cerulenin, 40 µM C75, or 1 µM lovastatin. Blue, Hoechst 33342 (DNA); green, anti-lamin B1 (NE). Scale bar, 5 µm. (f) Circularity of 200 nuclei for each condition in Fig. S3 e. (g) FACS profiles of cells in each condition in Fig. S3 e. Source data are available for this figure: SourceData FS3.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal